Skip to main content
. 2019 Nov 25;33(12):13602–13616. doi: 10.1096/fj.201901098R

Figure 7.

Figure 7

A–C) BI suppresses LPS-mediated increase in monocyte and neutrophil chemokine CCL2, but not CCL4 or monocyte differentiating cytokine GM-CSF, in the BAL. LPS increases the levels of CCL2 (MCP-1; A), CCL4 (MIP-1β; B), and GM-CSF (C). BI suppresses the LPS-mediated increase in the levels of CCL2, but not CCL4 and GM-CSF. These 3 cytokines are barely detectable in the serum. D–F) BI suppresses LPS-mediated increase in neutrophil chemokine CCL3 levels, but promotes CXCL1 levels, whereas it has no effect on CXCL2, in the BAL. LPS increases the levels of all 3 neutrophil chemokines CCL3 (MIP-1α; D), CXCL1 (KC; E), and CXCL2 (MIP-2; F). BI has opposing effects on the LPS-mediated increase in the levels of CCL3 and CXCL1. These 3 cytokines do not vary among the 4 treatment conditions in the serum; n = 5 for each condition. +, mean. *P < 0.05, ***P < 0.001 (P = 0.2265 for LPS vs. BI + LPS for GM-CSF, P = 0.7997 for LPS vs. BI + LPS for CXCL2 in BAL).